52 patents
Page 3 of 3
Utility
Methods of Treating Schizophrenia
29 Apr 20
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia.
Seth HOPKINS, Kenneth KOBLAN, Antony LOEBEL, Ajay OGIRALA
Filed: 15 Feb 18
Utility
CorrectedMetabotrophic Glutamate Receptor 5 Modulators and Methods Use Thereof
11 Mar 20
Compounds that modulate GluR5 activity and methods of using the same are disclosed.
Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
Filed: 5 Dec 18
Utility
Methods of Treating Parkinson's Disease by Administration of Apomorphine to an Oral Mucosa
4 Mar 20
Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described.
Scott David BARNHART, Michael Clinton KOONS, Madhu Sudan HARIHARAN, Jordan DUBOW, Thierry BILBAULT, Anthony John GIOVINAZZO
Filed: 8 Sep 19
Utility
Sublingual Apomorphine
29 Jan 20
The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.
Anthony John GIOVINAZZO, David Bruce HEDDEN, Marc L. DE SOMER, Nathan John BRYSON
Filed: 7 Aug 19
Utility
Fused DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL Compounds and Analogs for Treating CNS Disorders
22 Jan 20
Milan CHYTIL, Sharon ENGEL, Taleen G. HANANIA, Vadim ALEXANDROV, Emer LEAHY
Filed: 5 May 19
Utility
TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE
1 Jan 20
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed.
Thomas JERUSSI, Qun Kevin FANG, Mark G CURRIE
Filed: 9 May 19
Utility
1-HETEROCYCLYL Isochromanyl Compounds and Analogs for Treating CNS Disorders
25 Dec 19
Linghong Xie, Philip Glyn JONES, Kerry L. SPEAR, Noel Aaron POWELL, Taleen G. HANANIA, Vadim ALEXANDROV
Filed: 5 May 19
Utility
Salts of a Heterocyclic Compound and Crystalline Forms, Processes for Preparing, Therapeutic Uses, and Pharmaceutical Compositions Thereof
11 Dec 19
The present disclosure relates to salts of (R)-1-(3,4-dihydro-1H-[1,4]oxazino[4,3-b]indazol-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
Nandkumar Nivritti BHOGLE, Yuji FUJIWARA, Kenjiro HIRA, Tomoya KARASAWA, Kostas SARANTEAS, John R. SNOONIAN, Harold Scott WILKINSON, Haitao ZHANG
Filed: 5 Jun 19
Utility
Sublingual Films
4 Dec 19
The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
Nathan John BRYSON, Anthony John GIOVINAZZO, Scott David BARNHART, Michael Clinton KOONS
Filed: 9 May 19
Utility
Crystal Forms and Production Methods Thereof
16 Oct 19
The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same.
John R. Snoonian, Harold Scott Wilkinson
Filed: 20 Jun 19
Utility
Nonracemic Mixtures and Uses Thereof
16 Oct 19
Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
Filed: 25 Jun 19
Utility
Compounds and Compositions and Uses Thereof
9 Oct 19
Linghong Xie, Michele L.R. Heffernan, Philip Glyn Jones, Taleen G. Hanania
Filed: 9 Dec 18